

4/29/99

5.0 510(k) Summary

K990632

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR § 807.92.

1. The submitter of this premarket notification is:

Radionics Software Applications, Inc.
22 Terry Avenue
Burlington, MA 01803
Tel.: (781) 272-1233
Fax: (781) 272-2428
Contact Name: Lisa Misterka Benati

This summary was prepared on February 25, 1999.

2. The name of this device is:

Classification Name:	Stereotaxic instrument
Common/Usual Name:	Intraoperative Guidance Device
Proprietary Name:	Radionics Optical Tracking System (OTS)

3. This device is substantially equivalent to:

Radionics Optical Tracking System [K964801, K974602]

Surgical Navigation Technologies StealthStation Stereotactic System [K954276, K971247].

4. The submission describes a revised indications for use for the Optical Tracking System to provide for use in frameless cranial biopsy procedures.
5. The OTS is a graphical planning tool that allows for preoperative planning of, and intraoperative navigation during, cranial and spinal surgical procedures. Example procedures include, but are not limited to:

Catheter shunt placement
Vascular malformations
Frameless cranial biopsy
Various ENT procedures
Craniotomies
Tumor resections

Spinal implant procedures
Spinal biopsy
Laminectomy
Diskectomy
Decompression for spinal tumor.

6. The technological characteristics are the same or similar to those found in the predicate devices.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 29 1999

Ms. Lisa Misterka Benati
Senior Regulatory Engineer
Radionics, Inc.
22 Terry Avenue
Burlington, Massachusetts 01803-2516

Re: K990632
Trade Name: Optical Tracking System (Modification)
Regulatory Class: II
Product Code: HAW
Dated: February 25, 1999
Received: February 26, 1999

Dear Ms. Benati:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 – Ms. Lisa Misterka Benati

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style with a large initial "C" and "W".

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure


510(k) Number (if known): K990632

Device Name: Optical Tracking System (OTS) - Revised Indications for Use

Indications for Use:

The OTS is a graphical planning tool that allows for preoperative planning of, and intraoperative navigation during, cranial and spinal surgical procedures. This includes use in frameless cranial biopsy procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of General Restorative Devices
510(k) Number K990632

Prescription Use
(Per 21 CFR 801.109)

~~OR~~ ~~Over-the-Counter Use~~